- Shield Therapeutics said European regulators had recommended marketing authorisation approval of its Feraccru treatment be extended to include all adults with iron deficiency, with or without anaemia.

The recommendation would now go forward to the European Commission for ratification and implementation over the next two-to-three months.

Feraccru, the company's lead asset, is currently approved and marketed in Europe for the treatment of iron deficiency anemia, initially in patients with inflammatory bowel disease.

At 2:18pm: [LON:STX] Shield Therapeutics Plc share price was +3p at 26.5p

Story provided by